These two are sold for different jobs. Juvelook is marketed as a skin booster; Sculptra is a volume treatment. Juvelook is poly-D,L-lactic acid, or PDLLA, combined with hyaluronic acid, made by VAIM Co. in South Korea. Sculptra is poly-L-lactic acid alone, mixed with sterile water before injection. Related polymers, different products, different targets.
Juvelook has no US FDA approval and no US clearance. Juvelook has no FDA premarket approval and no 510(k) clearance. It is marketed in South Korea and in CE-mark territories, and it reaches US clinics through grey-market channels. That is worth knowing before you compare anything else about it.
There is also no published trial of Juvelook. There is no peer-reviewed study of the branded product. What exists is a general materials literature on poly-D,L-lactic acid - which, among other things, records that PDLLA fillers can cause nodules and granulomas, possibly from incomplete reconstitution.
The skin-quality versus volume split is real, but Sculptra sits closer to the middle than people assume. Sculptra's newest US approval, granted in 2023, is for fine lines and wrinkles in the cheek region - a skin-quality endpoint, not a volume one, measured on a wrinkle scale in a randomized trial.
The hyaluronic acid is a carrier that also gives some immediate hydration; the polymer is the part meant to stimulate collagen.
The current US labelling describes 367.5 mg of powder per vial containing poly-L-lactic acid microparticles with sodium carboxymethylcellulose and mannitol.
Marketed as a collagen stimulator for texture, fine lines and overall skin condition rather than for restoring shape.
The 2009 approval covers nasolabial fold contour deficiencies and other facial wrinkles. The 2023 approval covers fine lines and wrinkles in the cheek region - which is a skin-quality claim, and the only one of the two that is.
No FDA premarket approval and no 510(k) record. Marketed in South Korea under the MFDS and in CE-mark territories, per vendor and clinic material.
Facial fat loss in people with HIV (3 August 2004), nasolabial folds and other facial wrinkles suited to a deep dermal cross-hatch technique (2009), fine lines and wrinkles in the cheek region (2023). The 2009 and 2023 indications both specify people who are immune-competent.
There is no published clinical trial of Juvelook in the medical literature. Vendor and clinic descriptions are not evidence.
The 2023 cheek study randomized 149 people at 13 US sites against no treatment, using the Galderma Cheek Wrinkles Scale: 70.7% responders at month 12 against 25.9% of controls, p<0.0001, and 76.9% responders at months 21 and 24 in the previously treated extension group. Mean age was 60.7 and 96.6% of participants were female. The sponsor was the manufacturer.
There is no published depth protocol for the branded product.
That wording is in the approved labelling. It is not a superficial treatment and it is not spread thinly across a field.
Hyaluronidase breaks down hyaluronic acid, so it acts on the carrier. It has no effect on poly-D,L-lactic acid. Dissolving the gel does not remove the polymer.
Hyaluronidase does nothing to poly-L-lactic acid, no reversal agent is approved, and the labelling does not mention one.
A 2024 materials review notes that PDLLA fillers can cause nodules and granulomas, possibly due to incomplete reconstitution. There is no rate for the branded product, because there is no study of it.
In the 2009 nasolabial fold trial, papules or nodules occurred in 17.2% of the Sculptra group against 12.8% of the collagen control group. In the 2023 cheek trial injection-site nodules were reported in 1.0% - one person, still present at study completion. The labelling records nodules starting at a median of 160 days.
There is no FDA category called skin booster. The phrase describes a way of injecting - small amounts, spread superficially over an area, aimed at how skin looks rather than at where it sits - and it is applied to a long list of unrelated products.
That matters here because the phrase is doing most of the work in Juvelook's positioning. No regulator has assessed Juvelook against a skin-quality endpoint, because no regulator has assessed Juvelook. There is no published trial, no validated scale result, and no follow-up figure for the branded product. Anything specific you read about how long it lasts or what percentage of people improve did not come from a study of it.
Sculptra sits on the other side of that line. Its 2023 approval was granted on a randomized, evaluator-blinded trial using a named wrinkle scale, and the wording of the indication - fine lines and wrinkles in the cheek region - is public. You can read the indication and the trial that produced it. The trade-off is that the trial was run by the company that sells the product, which is true of almost every filler registration study.
The clean version of the split is this. A skin booster is aimed at the surface: texture, fine crepey lines, how light sits on the skin. A volumiser is aimed at structure: a hollow cheek, a fold, a face that has deflated.
The clean version is not quite right for Sculptra, and this is the most useful thing this page can tell you. Sculptra has two separate cosmetic indications and they are not the same kind of claim. The 2009 one is about fold contour - a structural claim. The 2023 one is about fine lines and wrinkles in the cheek region - a surface claim. So a reader choosing between a skin booster and Sculptra is not choosing between skin and shape. They are choosing between a product with no published evidence and a product with a randomized trial for one of the two things they want.
What Sculptra does not do is act on the day. It builds over weeks and months, which is the same slow curve any collagen stimulator has, whichever isomer of lactic acid it is built from.
Poly-L-lactic acid and poly-D,L-lactic acid are both polymers of lactic acid. They differ in the arrangement of the lactic acid units, which changes how the polymer packs together and how it breaks down. Both are used as collagen stimulators, and both provoke a slow response from the body rather than filling a space.
The published PDLLA literature is a materials literature, not a clinical trial literature. The most quotable finding in it for a patient is a caution: a 2024 review notes that PDLLA fillers can cause nodules and granulomas, possibly due to incomplete reconstitution. Incomplete reconstitution means the powder was not fully and evenly mixed before injection, leaving clumps. That is a preparation problem, and it is the same mechanism blamed for poly-L-lactic acid nodules.
It is worth being clear about what is not known. There is no published nodule rate for Juvelook. There is no published duration figure for Juvelook. There is no published depth or dilution protocol for Juvelook that comes from a primary manufacturer document rather than a vendor page.
Juvelook is widely sold into US clinics through grey-market channels. If you are offered it in the US, you are being offered a product with no FDA review behind it, and one whose supply chain the FDA has not inspected.
The FDA's consumer guidance on this is direct: do not buy dermal fillers sold directly to the public, and products sold that way may be fake, contaminated, or not approved for use in the US. A 2026 hospital series of injectable complications found that over half the products involved were uncertified or of unknown origin.
None of that says Juvelook harms people. It says that if something goes wrong, the ordinary trail - a reviewed label, a documented lot, a reporting route - may not exist.
Go to an emergency department or call 911 for any of these after either treatment:
Sudden change or loss of vision in either eye
Sudden severe pain, or pain out of proportion to the procedure
Skin turning white or blanched, then dusky, grey or mottled
Weakness, drooping, slurred speech or any stroke-like symptom
These can mean material has entered an artery, and the window is measured in hours. A superficial injection technique lowers this risk but does not remove it, and neither polymer can be dissolved.
Swelling keeps increasing after the first few days instead of settling
A firm lump appears under the skin, whether at three weeks or at six months
Redness spreads outward from a treated area, or you develop a fever
An area becomes tender or swollen weeks later, particularly after an illness, a vaccination or dental work
Small bumps appear along the lines where the product was placed